See more : Morepen Laboratories Limited (MOREPENLAB.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Invivyd, Inc. (IVVD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invivyd, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Emu NL (EMU.AX) Income Statement Analysis – Financial Results
- Electrolux Professional AB (publ) (EPRO-B.ST) Income Statement Analysis – Financial Results
- Tern Plc (TERNF) Income Statement Analysis – Financial Results
- Sopra Steria Group SA (SPSAF) Income Statement Analysis – Financial Results
- MFS Intercorp Limited (MFSINTRCRP.BO) Income Statement Analysis – Financial Results
Invivyd, Inc. (IVVD)
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.03M | 462.00K | 1.00K | 0.00 |
| Gross Profit | -2.03M | -462.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 158.66M | 179.21M | 182.89M | 62.12M |
| General & Administrative | 0.00 | 47.04M | 36.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.10M | 47.04M | 36.52M | 3.21M |
| Other Expenses | 0.00 | 6.71M | 118.00K | 0.00 |
| Operating Expenses | 205.76M | 226.26M | 219.41M | 65.33M |
| Cost & Expenses | 207.78M | 226.26M | 219.41M | 65.33M |
| Interest Income | 0.00 | 6.71M | 118.00K | 8.00K |
| Interest Expense | 0.00 | 43.08M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.03M | 462.00K | 1.00K | 43.20M |
| EBITDA | -196.62M | -248.03M | -226.79M | -65.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.78M | -248.03M | -226.91M | -65.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.14M | 6.71M | -7.38M | 8.00K |
| Income Before Tax | -198.64M | -241.32M | -226.79M | -65.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.71M | 7.50M | -43.20K |
| Net Income | -198.64M | -234.60M | -234.29M | -65.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.81 | -2.17 | -2.11 | -0.59 |
| EPS Diluted | -1.81 | -2.17 | -2.11 | -0.59 |
| Weighted Avg Shares Out | 109.53M | 108.27M | 110.78M | 111.25M |
| Weighted Avg Shares Out (Dil) | 109.53M | 108.27M | 110.78M | 111.25M |
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that PEMGARDA™ (pemivibart), formerly VYD222, a half-life extended monoclonal antibody (mAb),...
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, Chief Executive Officer of Invivyd, is scheduled to...
3 Groundbreaking Biotech Stocks to Invest in Now
Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company before it releases positive results. But on the flip side, a...
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
Invivyd is developing an experimental antibody treatment to prevent COVID-19 in immunocompromised patients. An estimated 9 million immunocompromised patients in the U.S. don't respond strongly enough to today's COVID-19 vaccines.
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants Data supportive of an immunobridging approach to the EVADE study of adintrevimab Overall favorable safety and tolerability profile of VYD222 including no study drug-related serious adverse events (SAEs)...
Invivyd, Inc. (IVVD) Q3 2023 Earnings Call Transcript
Invivyd, Inc. (NASDAQ:IVVD ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Corporate Participants Scott Young - SVP, Investor Relations and Corporate Communications Dave Hering - Chief Executive Officer Pete Schmidt - Chief Medical Officer Jeremy Gowler...
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the quarter ended September 30, 2023, and...
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November...
Source: https://incomestatements.info
Category: Stock Reports